Abstract. Our previous study demonstrated that 2-[(3-methoxybenzyl)oxy]benzaldehyde (CCY-1a-E2) is a potent compound that acts against multiple human leukemia cell lines. CCY-1a-E2 was also shown to have efficacious anti-leukemic activity in vivo. However, the molecular mechanism of action of CCY-1a-E2 attributed to its anticancer effect remains poorly understood. In the present study, CCY-1a-E2 suppressed cell viability in multiple leukemia cell lines (HL-60, K562, KG-1 and KG-1a) via inhibition of cell proliferation, cell cycle arrest and induction of apoptosis. CCY-1a-E2 exhibited a marked toxic effect on HL-60 cells and displayed low cytotoxicity in normal human peripheral blood mononuclear cells (PBMCs). Results from flow cytometric analysis indicated that CCY-1a-E2 promoted G2/M phase arrest and promoted apoptosis in the HL-60 cells. CCY-1a-E2 treatment upregulated cyclin B, cyclin-dependent kinase 1 (CDK1), cell division cycle 25C (cdc25C) and p21 protein expression. CCY-1a-E2 caused apoptotic cell death and DNA fragmentation as determined by 4' ,6-diamidino-2-phenylindole (DAPI) staining and DNA gel electrophoresis. Elevated activities of caspase-8, -9 and -3 were observed during CCY-1a-E2-induced cell apoptosis; their specific inhibitors were found to block CCY-1a-E2-induced apoptosis, respectively. Moreover, CCY-1a-E2 time-dependently disrupted the mitochondrial membrane potential (ΔΨm), and it enhanced the protein levels of Fas/CD95, cytochrome c, Bax, cleaved PARP, as well as attenuated Bcl-2 expression in the HL-60 cells. Our results provide direct evidence that supports the future potential therapeutic application of CCY-1a-E2 in leukemia.
Introduction
Leukemia is characterized by uncontrolled cell proliferation and blockage in the differentiation of hematopoietic cells (1, 2) . However, clinical trials concerning treatment strategies for leukemia have not achieved satisfactory outcomes, and new targets for treating leukemia are necessary. One of the best strategies for new anti-leukemia agents are carried out via induction of cell differentiation or apoptotic death in leukemia cells (3) (4) (5) . Regulation and/or management of cell cycle progression and apoptosis are prominent approaches to anti-leukemia therapy (2, 6) . Cyclin-dependent kinase (CDK) complexes can modulate cell cycle progression, especially cyclin-dependent kinase 1 (CDK1) and cyclin B are pivotal molecules in the regulation of the cell cycle in the G2/M phase (7, 8) . The cell division cycle 25C (cdc25C) phosphatase controls CDK1 activity and accelerates mitosis entry by dephosphorylation of CDK1 on Thr14 and Tyr15 sites (9, 10) . Additionally, the activity of CDK1/cyclin B complex is blocked by p21 waf/cip1 signaling which serves as a CDK inhibitor (11, 12) . Several agents have been shown to interfere with the activity of CDK1 and cause subsequent cell cycle arrest, and these agents have been developed into significant clinical anticancer drugs through induction of cancer cell apoptosis (13, 14) . When tumor cells undergo apoptosis, nuclear condensation, DNA fragmentation and apoptotic bodies are manifested (15, 16) . During the apoptotic process, caspase proteins undergo proteolytic processing and trigger a cascade of caspase activation (17, 18) . Therefore, these key factors can regulate the apoptotic process and play a vital role in the treatment of leukemia.
Benzyloxybenzaldehyde derivatives have been reported to have multiple biological functions, including binding to estrogen receptors (ERα and β), arresting cell cycle CCY-1a-E2 induces G2/M phase arrest and apoptotic cell death in HL-60 leukemia cells through cyclin-dependent kinase 1 signaling and the mitochondria-dependent caspase pathway progression and inducing apoptotic cell death (19) (20) (21) . A class of 2-benzyloxybenzaldehyde derivatives was designed and synthesized in our laboratory (20) . 2-Benzyloxybenzaldehyde analog 2-[(3-methoxybenzyl)oxy]benzaldehyde (CCY-1a-E2) has been found to be a potent compound against leukemia cells. CCY-1a-E2 exhibited an anti-leukemic effect on a leukemia BALB/c mouse model (19) . High dosage treatment (100 mg/kg) of CCY-1a-E2 was found to have no adverse effects on renal, hepatic and hematological parameters upon safety evaluation analysis (19) . However, the molecular mechanism underlying the anti-leukemia effects of CCY-1a-E2 has not been completely clarified. Here, the anti-proliferative activity of CCY-1a-E2 was evaluated in human leukemia HL-60 cells. We found that CCY-1a-E2 led to cell cycle arrest at the G2/M phase and caused apoptosis in HL-60 cells through mitochondria-dependent caspase cascade signaling. 2 culture flasks and were grown in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37˚C under a humidified atmosphere of 5% CO 2 and 95% air.
Materials and methods

Chemicals
Detection of cell number and viability. HL-60, K562, KG-1 and KG-1a cells (1x10 4 cells/well) in 96-well plates were incubated with 0, 1, 2.5, 5 and 10 µM of CCY-1a-E2 for 24 and 48 h. The trypan blue dye exclusion assay was applied to determine the number of viable cells by using a Countess Automated Cell Counter (Thermo Fisher Scientific, Inc.) as previously reported (22) . HL-60 cells were exposed to 0, 1, 2.5, 5 and 10 µM of CCY-1a-E2 after pre-incubation with or without 10, 25 and 50 µM of Z-IETD-FMK, Z-LEHD-FMK and Z-DEVD-FMK for 2 h. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed for the quantitative analysis of cell viability as described elsewhere (23, 24) .
Assessment of cell cycle distribution by flow cytometric analysis. HL-60 cells (2x10
5 cells/well) were seeded into 12-well plates and then treated with 5 µM CCY-1a-E2 for 0, 3, 6, 12 and 24 h. The cells were fixed and stained with propidium iodide (PI) solution following a previously reported method (6). The sub-G1 peak (apoptotic population) and cell cycle profiling were determined using a BD FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA), and the data were analyzed by utilizing BD CellQuest software.
Immunoblotting analysis. HL-60 cells (1x10 7 cells) were placed in T75 flasks and treated with 5 µM CCY-1a-E2 for 0, 1, 2, 4, 6, 8, 10, 12 and 16 h. After treatments, the cells were lysed with lysis buffer, and each sample was electrophoresed as previously detailed (15, 22, 25) , and the membrane was probed with an appropriate secondary antibody for enhanced chemiluminescence (Immobilon Western HRP Substrate; Merck Millipore, Bedford, MA, USA).
4',6-Diamidino-2-phenylindole (DAPI) staining and DNA fragmentation assay. HL-60 cells (2x10
5 cells/ml) were treated with 5 µM CCY-1a-E2 for 24 h and thereafter stained with 1 µg/ml DAPI as previously described (16, 25) . After a 48-h exposure, DNA was extracted from each sample and electrophoresis was run according to a previous method (26) .
Analyses of caspase-3, -8 and -9 activities. HL-60 cells at a density of 1x10
7 cells/flask were incubated with 5 µM CCY-1a-E2 for 0, 2, 4, 8 and 12 h. At the end of the incubation, the cells were lysed and assessed according to the manufacturer's instructions provided in the Caspase-3, -8 and -9 Colorimetric Assay kits (R&D Systems, Inc.).
Determination of mitochondrial membrane potential (ΔΨm).
HL-60 cells at a density of 2x10 5 cells/well in 12-well plates were treated with 5 µM CCY-1a-E2 for 0, 6, 12, 18 and 24 h. Cells from each treatment were harvested and re-suspended in 500 µl of DiOC 6 (3) (Thermo Fisher Scientific, Inc.) at 50 nM for ΔΨm. After incubation at 37˚C for 30 min, the cells were analyzed by flow cytometry as described by Lee et al (27) .
Statistical analysis. The statistical significance of the difference was defined (p<0.05) and carried out utilizing Student's t-test, and the data are expressed as the mean ± standard deviation (SD) from three independent experiments.
Results
CCY-1a-E2 reduces cell viability in leukemia cells.
Four cell lines (HL-60, K562, KG-1 and KG-1a) were used to assess the cytotoxicity of CCY-1a-E2. The cells were treated with 0, 1, 2.5, 5 and 10 µM of CCY-1a-E2 for 24 h, and the viable cell number was measured by trypan blue dye exclusion assay. CCY-1a-E2 dose-dependently decreased the viability of the HL-60, K562, KG-1 and KG-1a cells. Notaby, HL-60 cells were more sensitive to CCY-1a-E2 than the three other cell lines (Fig. 1A) .
In addition, the inhibitory effect of CCY-1a-E2 on the proliferation of HL-60 cells was time-dependent (Fig. 1B) , and the half maximal inhibitory concentration (IC 50 ) value for the 48-h treatment of CCY-1a-E2 in the HL-60 cell line was 5.32±0.25 µM. In contrast, CCY-1a-E2 exerted low cytotoxicity against normal human PBMCs (Fig. 2) . Our results suggest that CCY-1a-E2 exhibits anti-leukemia action against HL-60 cells in vitro.
CCY-1a-E2 causes G2/M phase arrest in HL-60 cells.
To explore the effect of CCY-1a-E2 on cell cycle distribution, the cells were treated for various time periods with CCY-1a-E2. The percentage of treated cells in phase G1, S and G2/M was detected by DNA content stained with PI. CCY-1a-E2 induced G2/M phase arrest and increased the sub-G1 population (apoptotic cells) (Fig. 3A) . Exposure of HL-60 cells to 5 µM CCY-1a-E2 for 6, 12 and 24 h resulted in a significant increase in the percentage of cells in the G2/M phase, while a marked decrease in the percentage of cells in the G0/G1 phase was observed (Fig. 3B) . To examine the protein levels associated with the G2/M phase, CCY-1a-E2-treated cells were analyzed by immunoblotting. The protein expression levels of cyclin B, CDK1, cdc25C were increased. However, after 6 hours of treatment, cdc25C protein level gradually decreased, but p21 protein level significantly increased (Fig. 4) . These findings suggest that CCY-1a-E2 regulated CDK1 activation and resulted in G2/M phase arrest in the HL-60 cells.
CCY-1a-E2 triggers apoptotic death in HL-60 cells. In Fig. 3 , the percentage of cells in the sub-G1 phase (apoptotic cells) . CCY-1a-E2 has no effect on the viability of normal PBMCs. Normal PBMCs were incubated with various concentrations of CCY-1a-E2 for 24 and 48 h, and the cell viability was measured by MTT assay as described in ʻMaterials and methods'. The results are presented as the means ± SD (n=3). PBMCs, peripheral blood mononuclear cells; SD, standard deviation.
was increased after CCY-1a-E2 exposure. To evaluate whether CCY-1a-E2 induces apoptosis, we performed DAPI staining for chromatin condensation and a DNA fragmentation assay. The number of cells with brighter cell nuclei were elevated in the CCY-1a-E2-treated cells (Fig. 5A ). In addition, DNA was extracted from the cells following treatment with various concentrations of CCY-1a-E2 for 24 h, and subjected to agarose gel electrophoresis. DNA ladder was observed in samples treated with 5, 10 and 15 µM CCY-1a-E2 (Fig. 5B) . Our results imply that CCY-1a-E2 treatment induced apoptosis in the HL-60 cells.
CCY-1a-E2 enhances caspase-9, -8 and -3 activities in HL-60 cells.
To further ascertain whether CCY-1a-E2-induced apoptosis is caspase-dependent, we performed specific caspase activity assays. HL-60 cells were exposed to 5 µM CCY-1a-E2 for different time periods. We found that CCY-1a-E2 enhanced the activities of caspase-9, -3 and -8 (Fig. 6A) after 2, 4, 8 and 12 h of exposure. To confirm the role of caspase-mediated apoptosis by CCY-1a-E2, the cells were pre-treated with specific caspase inhibitors. Our data showed that Z-IETD-FMK, Z-LEHD-FMK and Z-DEVE-FMK at 10, 25 and 50 µM concentration-dependently suppressed CCY-1a-E2-reduced cell viability (Fig. 6B) . These data indicated that CCY-1a-E2-induced apoptosis was mediated via both extrinsic and intrinsic signaling in the HL-60 cells.
CCY-1a-E2 collapses ΔΨm and alters mitochondria-mediated apoptosis signaling in HL-60 cells.
To confirm whether the CCY-1a-E2-provoked apoptosis was mediated via the mitochondrial pathway, the level of ΔΨm was measured and immunoblotting was carried out. CCY-1a-E2 treatment led to a decrease in ΔΨm in a time-course pattern (Fig. 7) . CCY-1a-E2 also promoted the protein expression of cytochrome c, Bax and PARP, while it suppressed the level of Bcl-2 (Fig. 8) . Additionally, activation of Fas/CD95 protein occurred in the treated cells (Fig. 8) . Therefore, these results conclude that CCY-1a-E2-mediated apoptosis of HL-60 cells was carried out through the mitochondria-and death receptor-dependent pathway.
Discussion
2-Benzyloxybenzaldehyde (CCY-1a) has been shown to inhibit superoxide anion generation via Akt inactivation and phospholipase D activation in rat neutrophils (21) . In addition, 2-benzyloxybenzaldehyde can block Ca 2+ entry and suppress formyl peptide-stimulated increase in intracellular Ca 2+ in neutrophils (28). Pan et al (29) demonstrated that 2-benzyloxybenzaldehyde modulates vascular smooth muscle cell proliferation by blocking the Ras/p42/44 MAPK pathway and inhibiting NF-κB and AP-1 DNA binding activities. Our previous study showed that CCY-1a-E2 reduced the percentage of viable murine leukemia WEHI-3 cells, and the IC 50 value of CCY-1a-E2 was 5 µM for a 24-h treatment (19) . To evaluate the anticancer effect of CCY-1a-E2 on other leukemia cell lines, we treated HL-60, K562, KG-1 and KG-1a cells with various concentrations of CCY-1a-E2. A significant concentration-dependent decrease of cell viability was observed in all cell lines after 24 h exposure to 2.5-10 µM of CCY-1a-E2. CCY-1a-E2 not only decreased the cell viability in HL-60 cells, but also exerted low cytotoxicity in PBMCs ( Figs. 1 and 2 ). The clinical applicability of an anti-leukemia drug depends on its being distinct in both its potency and therapeutic index between leukemia and normal blood cells (6) . Our result was in agreement with the previous study of CCY-1a-E2 on reducing viability of WEHI-3 cells (19) . Overall, CCY-1a-E2 represents a promising candidate as an anticancer agent for leukemia due to its low toxicity to normal cells. CCY-1a-E2 significantly inhibited cell viability and induced cell apoptosis in the HL-60 cells (Figs. 1 and 3) . However, the molecular mechanisms of its anti-leukemia activity remain unknown. Our data demonstrated that CCY-1a-E2 triggered cell cycle arrest at the G2/M phase after a 6-h exposure, while its effect on the sub-G1 cell population appeared following a 12-h treatment (Fig. 3A) . This result indicated that CCY-1a-E2-induced G2/M phase arrest occurred before the onset of apoptosis. The CDK1/cyclin B complex is one of the main regulators, resulting in G2/M progression and apoptosis. G2/M checkpoints can be exerted by inactivating cdc25C and activating CDK inhibitor (p21waf/cip), which subsequently inactivates CDK1, and prevents cells from entering mitosis (9, 12) . In the present study, we investigated Figure 8 . CCY-1a-E2 affects the levels of apoptosis-related proteins in the HL-60 cells. The cells were treated with 5 µM CCY-1a-E2 for the indicated time intervals, and the total proteins were prepared and detected by western blot analysis as described in ʻMaterials and methods'. The blot was individually probed with the specific primary antibodies for Fas/CD95, cytochrome c, Bcl-2, Bax and PARP, and α-tubulin served as an internal control. the expression levels of G2/M phase-related proteins. Our results demonstrated that CCY-1a-E2 induced the expression of cyclin B, CDK1, cdc25C and p21 in a time-dependent manner (Fig. 4) . Our finding implicates a novel role for the 2-benzyloxybenzaldehyde derivative.
Cells undergo apoptosis in response to cell death-inducing signals from death receptors on the cell surface [such as Fas, death receptor 4 (DR4) or DR5], mitochondria, or endoplasmic reticulum (ER) stress (30) (31) (32) . During apoptosis, caspases are activated and arranged in a proteolytic cascade to convey the apoptotic signal (17, 18) . Apoptotic evidence of chromatin condensation and DNA fragmentation was observed in the CCY-1a-E2-treated HL-60 cells, indicating that cells underwent apoptosis in response to CCY-1a-E2 treatment (Fig. 5) . Moreover, induction of caspase-9, -8 and -3 activities (Fig. 6) as well as the specific cleavage of PARP (Fig. 8) were detected in the CCY-1a-E2-treated cells. Application of the intrinsic and extrinsic caspase specific inhibitors blocked the CCY-1a-E2-reduced cell viability (Fig. 6 ). This result further confirmed the effect of CCY-1a-E2 on apoptotic pathways. The caspase-independent factors such as apoptosis-inducing factor (AIF) and endonuclease G (Endo G) can be released from mitochondria into the cytosol (33, 34) . Our results fail to exclude the possibility of a caspase-independent pathway involved in the CCY-1a-E2-induced apoptosis.
Loss of ΔΨm is one of the features of apoptosis (35, 36) . Indeed, we detected a significant loss of ΔΨm in the CCY-1a-E2-treated HL-60 cells (Fig. 7) . Moreover, cytochrome c release is related to the change in Bcl-2 family proteins during cell apoptosis. Bcl-2 and Bax are located in the mitochondrial outer membrane, and their ratio (Bcl-2/Bax) regulates the release of apoptotic elements (cytochrome c, pro-caspase-9, AIF and Endo G) to the cytosol (18, 31, 35) . Our data indicated that the protein expression levels of cytochrome c, Bax and PARP (p85) were increased, whereas the protein expression level of Bcl-2 was decreased in the CCY-1a-E2-treated HL-60 cells (Fig. 8) . Our results are consistent with these available observations as evidenced by the upregulation of Bax protein and the downregulation of Bcl-2 protein in the CCY-1a-E2-treated cells. These results suggest that the activation of the caspase cascade contributed to CCY-1a-E2-induced apoptosis of HL-60 cells.
In conclusion, we demonstrated that CCY-1a-E2 exerts cytotoxic activity against leukemia cells, while it is less toxic to normal PBMCs. CCY-1a-E2 induced G2/M phase arrest followed by caspase-mediated apoptosis in the human leukemia HL-60 cells. Taken together, these findings provide important new insights into the possible molecular mechanisms of the anti-leukemia activity of CCY-1a-E2.
